Pulmonary arterial hypertension: pathophysiology and treatment
NSH Lan, BD Massam, SS Kulkarni, CC Lang - Diseases, 2018 - mdpi.com
Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a
chronic and progressive disorder characterised by angioproliferative vasculopathy in the …
chronic and progressive disorder characterised by angioproliferative vasculopathy in the …
Pulmonary arterial hypertension: tailoring treatment to risk in the current era
S Gaine, V McLaughlin - European Respiratory Review, 2017 - Eur Respiratory Soc
Recent advances in the treatment of pulmonary arterial hypertension (PAH) have led to
improved patient outcomes. Multiple PAH therapies are now available and optimising the …
improved patient outcomes. Multiple PAH therapies are now available and optimising the …
Pulmonary arterial hypertension: challenges in translational research and a vision for change
G Sutendra, ED Michelakis - Science translational medicine, 2013 - science.org
Pulmonary arterial hypertension (PAH) is a vascular remodeling disease with a relentless
course toward heart failure and early death. Existing PAH therapies, all of which were …
course toward heart failure and early death. Existing PAH therapies, all of which were …
The pharmacological treatment of pulmonary arterial hypertension
LR Frumkin - Pharmacological reviews, 2012 - ASPET
Pulmonary arterial hypertension (PAH) is a life-threatening and progressive disease of
various origins characterized by pulmonary vascular remodeling that leads to increased …
various origins characterized by pulmonary vascular remodeling that leads to increased …
Clinical trial design and new therapies for pulmonary arterial hypertension
O Sitbon, M Gomberg-Maitland… - European …, 2019 - Eur Respiratory Soc
Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on
case reports and small series, and was largely ineffectual. As a deeper understanding of the …
case reports and small series, and was largely ineffectual. As a deeper understanding of the …
Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
AR Hemnes, M Humbert - European Respiratory Review, 2017 - Eur Respiratory Soc
The pathobiology of pulmonary arterial hypertension (PAH) is complex and incompletely
understood. Although three pathogenic pathways have been relatively well characterised, it …
understood. Although three pathogenic pathways have been relatively well characterised, it …
Management of pulmonary arterial hypertension
JD Mayeux, IZ Pan, J Dechand, JA Jacobs… - Current cardiovascular …, 2021 - Springer
Abstract Purpose of Review This review focuses on the therapeutic management and
individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food …
individualized approach to Group 1 pulmonary arterial hypertension (PAH), utilizing Food …
Pulmonary arterial hypertension: pathogenesis and clinical management
Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm
Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of …
Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of …
Evidence-based pharmacologic management of pulmonary arterial hypertension
N Benedict, A Seybert, MA Mathier - Clinical therapeutics, 2007 - Elsevier
Background: Pulmonary arterial hypertension (PAH) is a debilitating chronic disorder of the
pulmonary vasculature characterized by elevated mean pulmonary arterial pressure, right …
pulmonary vasculature characterized by elevated mean pulmonary arterial pressure, right …
[HTML][HTML] Current and emerging therapeutic approaches to pulmonary hypertension
Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of
multifactorial etiology. Most of the available drugs and FDA-approved therapies for treating …
multifactorial etiology. Most of the available drugs and FDA-approved therapies for treating …